Tornalate will be marketed by Dura's 92- member national field sales force which targets respiratory specialists.
Tornalate Inhalation Solution adds a bronchodilator beta agonist to Dura's product line and is prescribed in the asthma drug market.
Tornalate Inhalation Solution sales will also support sales of Dura's Tornalate Metered Dose Inhaler (MDI), also recently licensed from Sterling Winthrop Inc.
The benefits of Tornalate include rapid and pronounced bronchodilation (opening of the airways in the lung) and duration of action.
Tornalate (bitolterol mesylate) was developed by Sterling Winthrop Inc.